查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594472

神經生物標記物市場：按類型、應用和最終用戶分類 - 2025-2030 年全球預測

Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

神經生物標記市場2023年估值為89.8億美元，預計到2024年將達到102.4億美元，複合年成長率為14.05%，到2030年將達到225.6億美元。

神經生物標記是與中樞神經系統相關的生物狀況的可測量指標，已成為神經系統疾病診斷和治療的關鍵工具。隨著生物標記的定義不斷擴大，它已包括遺傳標記、蛋白質和表明大腦功能和結構變化的成像觀察。阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的盛行率不斷上升證明了這一需求，早期準確的診斷可顯著改善患者的預後。這些生物標記可應用於藥物開發、監測疾病進展和客製化治療策略，最終用途包括研究機構、醫療機構和製藥公司。市場成長的關鍵驅動力是神經系統疾病盛行率的上升、生物標記技術的進步、研究經費的增加。主要商機在於非侵入性生物標記的開發及其與人工智慧的整合，以提高診斷準確性。創新是神經系統疾病液態切片以及基因組學和蛋白​​質組學融合等領域的關鍵。然而，市場開拓受到監管複雜性、研發高成本以及新型生物標記候選物臨床檢驗限制等挑戰的阻礙。此外，對生物標記研究的倫理影響和病人隱私的擔憂構成了重大障礙。為了克服這些問題，相關人員應專注於簡化監管途徑、促進公私合作以及倡導道德準則和病患資料保護。神經生物標記市場的本質是動態的、多學科的，需要神經科學家、生物技術專家和醫學專業人士採取協同方法。為了實現永續的業務成長，公司需要投資強力的研發，探索與學術研究機構的合作機會，並瞄準醫療基礎設施正在改善的新興市場。採用這些策略可以加強競爭並擴大神經生物標記對全球醫療保健的影響。

主要市場統計
基準年[2023] 89.8億美元
預測年份 [2024] 102.4億美元
預測年份 [2030] 225.6億美元
複合年成長率（%） 14.05%

市場動態：揭示快速發展的神經生物標記物市場的關鍵市場洞察

供需的動態交互作用正在改變神經生物標記市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 神經系統疾病盛行率增加
    • 對具有成本效益的非侵入性診斷系統的需求
    • 人們越來越偏好早期診斷和預防性治療
  • 市場限制因素
    • 嚴格的政府核准規定
  • 市場機會
    • 越來越關注生物標記進步的研究和開發
    • 單細胞生物感測器的興起
    • 開發中國家低成本臨床試驗的增加
  • 市場問題
    • 倫理問題和神經系統疾病的接受問題

波特的五力：駕馭神經生物標記市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經生物標記物市場的外部影響

外部宏觀環境因素在塑造神經生物標記市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解神經生物標記市場的競爭格局

神經生物標記物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：神經生物標記物市場供應商的績效評估

FPNV 定位矩陣是評估神經生物標記市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製神經生物標記物市場的成功之路

神經生物標記物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 神經系統疾病增加
      • 對具有成本效益和非侵入性診斷系統的需求
      • 對早期診斷和預防性治療的興趣增加
    • 抑制因素
      • 有關核准的嚴格政府法規
    • 機會
      • 擴大研發重點以促進生物標記的發展
      • 新型單細胞生物感測器
      • 新興國家低成本臨床試驗的增加
    • 任務
      • 倫理問題和神經系統疾病的接受問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章神經生物標記市場：依類型

  • 介紹
  • 基因組
  • 影像
  • 代謝體學
  • 蛋白質體

第7章神經生物標記市場：依應用分類

  • 介紹
  • 阿茲海默症
  • 泛自閉症障礙
  • 多發性硬化症
  • 帕金森氏症

第 8 章 神經生物標記市場：依最終用戶分類

  • 介紹
  • 醫院實驗室
  • 獨立臨床診斷中心
  • 研究所

第9章美洲神經生物標記市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太神經生物標記市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的神經生物標記市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Acumen Pharmaceuticals, Inc
  • Alseres Pharmaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Imagilys
  • inviCRO, LLC by Konica Minolta Business Solutions USA, Inc.
  • IXICO PLC
  • Merck KGaA
  • Proteome Sciences PLC
  • QIAGEN GmbH
  • Quanterix Corporation
  • Quest Diagnostics Incorporated
  • Rules-Based Medicine by Q2 Solutions
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AD36CD897EE7

The Neurological Biomarkers Market was valued at USD 8.98 billion in 2023, expected to reach USD 10.24 billion in 2024, and is projected to grow at a CAGR of 14.05%, to USD 22.56 billion by 2030.

Neurological biomarkers, measurable indicators of a biological condition related to the central nervous system, have emerged as crucial tools in diagnosing and managing neurological diseases. As their definition broadens, these biomarkers include genetic markers, proteins, and imaging findings that signal changes in brain function or structure. Their necessity is underscored by the increasing prevalence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, where early and accurate diagnosis can significantly improve patient outcomes. These biomarkers find application in drug development, monitoring disease progression, and customizing therapeutic strategies, with end-use spanning research institutions, healthcare facilities, and pharmaceutical companies. Market growth is primarily driven by the rising incidence of neurological conditions, advancements in biomarker technology, and increased research funding. Key opportunities lie in the development of non-invasive biomarkers and integration with artificial intelligence to enhance diagnostic precision. Innovation is critical in areas like liquid biopsy for neurological conditions and the convergence of genomics and proteomics. However, market growth is hindered by challenges such as regulatory complexities, high costs of research and development, and limited clinical validation of new biomarker candidates. Additionally, the ethical implications of biomarker research and patient privacy concerns pose significant barriers. To overcome these, stakeholders should focus on streamlining regulatory pathways, fostering public-private collaborations, and advocating for ethical guidelines and patient data protection. The nature of the neurological biomarkers market is dynamic and interdisciplinary, demanding a synergistic approach among neuroscientists, biotechnologists, and healthcare professionals. For sustained business growth, companies should invest in robust R&D, explore collaboration opportunities with academic and research institutions, and target emerging markets where healthcare infrastructure is improving. Embracing these strategies will enhance competitiveness and expand the impact of neurological biomarkers on global healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 8.98 billion
Estimated Year [2024] USD 10.24 billion
Forecast Year [2030] USD 22.56 billion
CAGR (%) 14.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurological Biomarkers Market

The Neurological Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of neurological disorders
    • Demand for cost-effective and non-invasive diagnostic system
    • Increasing preferences on early diagnosis & preventive treatment
  • Market Restraints
    • Stringent government regulations for approvals
  • Market Opportunities
    • Growing R&D focus for advancements in biomarkers
    • Emerging single-cell biosensors
    • Growth of low-cost clinical trials in developing countries
  • Market Challenges
    • Ethical problems and acceptance issues of neurological disorders

Porter's Five Forces: A Strategic Tool for Navigating the Neurological Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurological Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurological Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurological Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurological Biomarkers Market

A detailed market share analysis in the Neurological Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurological Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurological Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurological Biomarkers Market

A strategic analysis of the Neurological Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurological Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acumen Pharmaceuticals, Inc, Alseres Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Imagilys, inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc., IXICO PLC, Merck KGaA, Proteome Sciences PLC, QIAGEN GmbH, Quanterix Corporation, Quest Diagnostics Incorporated, Rules-Based Medicine by Q2 Solutions, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Neurological Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Genomic, Imaging, Metabolomic, and Proteomic.
  • Based on Application, market is studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.
  • Based on End-user, market is studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders
      • 5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
      • 5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent government regulations for approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing R&D focus for advancements in biomarkers
      • 5.1.3.2. Emerging single-cell biosensors
      • 5.1.3.3. Growth of low-cost clinical trials in developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical problems and acceptance issues of neurological disorders
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neurological Biomarkers Market, by Type

  • 6.1. Introduction
  • 6.2. Genomic
  • 6.3. Imaging
  • 6.4. Metabolomic
  • 6.5. Proteomic

7. Neurological Biomarkers Market, by Application

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Autism Spectrum Disorders
  • 7.4. Multiple Sclerosis
  • 7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospital Laboratories
  • 8.3. Independent Clinical Diagnostic Centers
  • 8.4. Research Organizations

9. Americas Neurological Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neurological Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acumen Pharmaceuticals, Inc
  • 3. Alseres Pharmaceuticals, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Imagilys
  • 7. inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
  • 8. IXICO PLC
  • 9. Merck KGaA
  • 10. Proteome Sciences PLC
  • 11. QIAGEN GmbH
  • 12. Quanterix Corporation
  • 13. Quest Diagnostics Incorporated
  • 14. Rules-Based Medicine by Q2 Solutions
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEUROLOGICAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023